CTOs on the Move

BrightCoach

www.bright.coach

 
BrightCoach is a rapidly growing innovator in the Coaching industry. It is a company of talented, experienced, executive business, and life coaches, dedicated to enriching lives and helping our clients achieve their desired goals. BrightCoach works closely with our clients to help them move forward in a unique one-on-one Coaching relationship to create positive change, leadership skills, active self-discovery and extraordinary results in their lives, careers, businesses or organizations. BrightCoach has developed a unique Coaching methodology combining today’s latest science of change within structured, personalized Coaching programs, to help our clients move from where they are - to where they ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

EmanciCare

EmanciCare is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Validic

Validic provides a simple connection to secure, standardized data from the newest, most popular and most specialized digital health technologies - from wellness applications and wearables to fitness equipment and clinical devices. Mobile health technologies are reshaping patient engagement and population management opportunities for healthcare companies. Validic is powering this ecosystem to allow for the accelerated deployment of healthcare companies` strategic initiatives. Validic`s clients include health systems and providers, health plans and payers, corporate wellness companies, pharmaceuticals, health IT vendors, as well as app and device manufacturers.

Axiom

Axiom is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxtel

Oxtel is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.